Publique en esta revista
Información de la revista
Vol. 65. Núm. 2.
Páginas 173 (Febrero 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 65. Núm. 2.
Páginas 173 (Febrero 2012)
DOI: 10.1016/j.recesp.2011.11.006
Acceso a texto completo
Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST
ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
Visitas
94853
Christian W. Hamma, Jean-Pierre Bassanda, Stefan Agewalla, Jeroen Baxa, Eric Boersmaa, Hector Buenoa, Pio Casoa, Dariusz Dudeka, Stephan Gielena, Kurt Hubera, Magnus Ohmana, Mark C. Petriea, Frank Sonntaga, Miguel Sousa Uvaa, Robert F. Storeya, William Wijnsa, Doron Zahgera
Contenido relaccionado
Rev Esp Cardiol. 2012;65:125-3010.1016/j.recesp.2011.12.003
Antonio Fernández-Ortiz, Manuel Pan, Fernando Alfonso, Fernando Arós, José A. Barrabés, Vicente Bodí, Ángel Cequier, Xavier García-Moll, Javier Jiménez-Candil, Ramón López-Palop, Carlos Peña, Fernando Worner, Ángel M. Alonso Gómez, Manuel Anguita, Josep Comín, Joaquín Alonso, Alfredo Bardají, Gonzalo Barón-Esquivias, Ramón Bover, Juan Ángel-Ferrer, Javier Goicolea, Juan J. Gómez-Doblas, Andrés Iñiguez, Vicente Mainar, Francisco Marín, Milagros Pedreira, Inmaculada Roldán, Manel Sabaté, Pedro L. Sánchez, Juan Sanchis
Este artículo ha recibido
94853
Visitas
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo
Referencias no citadas

(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320).

Recibido 22 Noviembre 2011

Aceptado 22 Noviembre 2011

Bibliografía
[1]
Murray CJ, Lopez AD..
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study..
Lancet. , 349 (1997), pp. 1498-1504
[2]
Van deWerf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et-al..
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology..
Eur Heart J. , 29 (2008), pp. 2909-2945
[3]
Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et-al..
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes..
Eur Heart J. , 28 (2007), pp. 1598-1660
[4]
Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS..
Population trends in the incidence and outcomes of acute myocardial infarction..
N Engl J Med. , 362 (2010), pp. 2155-2165
[5]
Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA..
The Global Registry of Acute Coronary Events, 1999 to 2009—GRACE..
Heart. , 96 (2010), pp. 1095-1101
[6]
Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafrici A, et-al..
Prognostic value of the admission electrocardiogram in acute coronary syndromes..
JAMA. , 281 (1999), pp. 707-713
[7]
Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, et-al..
The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004..
Eur Heart J. , 27 (2006), pp. 2285-2293
[8]
Terkelsen CJ, Lassen JF, Norgaard BL, Gerdes JC, Jensen T, Gotzsche LB, et-al..
Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort..
Eur Heart J. , 26 (2005), pp. 18-26
[9]
Hamm CW, M.llmann H, Bassand JP, Van deWerf F. Acute coronary syndrome. En: Camm AJ, Lüscher TF, Serruys PW, editores. The ESC Textbook of Cardiovascular Medicine. 2.a ed. Oxford: Oxford University Press; 2009..
[10]
Stone GW, Maehara A, Lansky AJ, De Bruyne B, Cristea E, Mintz GS, et-al..
A prospective natural-history study of coronary atherosclerosis..
N Engl J Med. , 364 (2011), pp. 226-235
[11]
Campeau L..
Grading of angina pectoris..
Circulation. , 54 (1976), pp. 522-523
[12]
Van Domburg RT, Van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML..
Unstable angina: good long-term outcome after a complicated early course..
J Am Coll Cardiol. , 31 (1998), pp. 1534-1539
[13]
Canto JG, Fincher C, Kiefe CI, Allison JJ, Li Q, Funkhouser E, et-al..
Atypical presentations among Medicare beneficiaries with unstable angina pectoris..
Am J Cardiol. , 90 (2002), pp. 248-253
[14]
Culic V, Eterovic D, Miric D, Silic N..
Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors..
Am Heart J. , 144 (2002), pp. 1012-1017
[15]
Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, et-al..
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events..
Chest. , 126 (2004), pp. 461-469
[16]
Lev EI, Battler A, Behar S, Porter A, Haim M, Boyko V, et-al..
Frequency, characteristics, and outcome of patients hospitalized with acute coronary syndromes with undetermined electrocardiographic patterns..
Am J Cardiol. , 91 (2003), pp. 224-227
[17]
Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV, Kirk JD, et-al..
Frequency and consequences of recording an electrocardiogram .10 min after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative)..
Am J Cardiol. , 97 (2006), pp. 437-442
[18]
Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et-al..
Universal definition of myocardial infarction..
Circulation. , 116 (2007), pp. 2634-2653
[19]
Okamatsu K, Takano M, Sakai S, Ishibashi F, Uemura R, Takano T, et-al..
Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes..
Circulation. , 109 (2004), pp. 465-470
[20]
Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et-al..
Sensitive troponin I assay in early diagnosis of acute myocardial infarction..
N Engl J Med. , 361 (2009), pp. 868-877
[21]
Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et-al..
Early diagnosis of myocardial infarction with sensitive cardiac troponin assays..
N Engl J Med. , 361 (2009), pp. 858-867
[22]
Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus HA..
High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission..
Clin Chem. , 56 (2010), pp. 642-650
[23]
Weber M, Bazzino O, Estrada JJN, Miguel R, Salzberg S, Fuselli JJ, et-al..
Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome..
Am Heart J. , 162 (2011), pp. 81-88
[24]
Omland T, De Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et-al..
A sensitive cardiac troponin T assay in stable coronary artery disease..
N Engl J Med. , 361 (2009), pp. 2538-2547
[25]
De Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et-al..
Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population..
JAMA. , 304 (2010), pp. 2503-2512
[26]
Otsuka T, Kawada T, Ibuki C, Seino Y..
Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease..
Am Heart J. , 159 (2010), pp. 972-978
[27]
Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et-al..
Recommendations for the use of cardiac troponin measurement in acute cardiac care..
Eur Heart J. , 31 (2010), pp. 2197-2204
[28]
Apple FS, Murakami MM, Pearce LA, Herzog CA..
Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease..
Circulation. , 106 (2002), pp. 2941-2945
[29]
Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, et-al..
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction..
N Engl J Med. , 346 (2002), pp. 2047-2052
[30]
Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T..
Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I..
N Engl J Med. , 337 (1997), pp. 1648-1653
[31]
Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R..
National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases..
Clin Chem. , 45 (1999), pp. 1104-1121
[32]
Than M, Cullen L, Reid CM, Lim SH, Aldous S, Ardagh MW, et-al..
A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study..
Lancet. , 377 (2011), pp. 1077-1084
[33]
Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et-al..
ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography)..
Circulation. , 108 (2003), pp. 1146-1162
[34]
Nucifora G, Badano LP, Sarraf-Zadegan N, Karavidas A, Trocino G, Scaffidi G, et-al..
Comparison of early dobutamine stress echocardiography and exercise electrocardiographic testing for management of patients presenting to the emergency department with chest pain..
Am J Cardiol. , 100 (2007), pp. 1068-1073
[35]
Kwong RY, Schussheim AE, Rekhraj S, Aletras AH, Geller N, Davis J, et-al..
Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging..
Circulation. , 107 (2003), pp. 531-537
[36]
Udelson JE, Beshansky JR, Ballin DS, Feldman JA, Griffith JL, Handler J, et-al..
Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial..
JAMA. , 288 (2002), pp. 2693-2700
[37]
Hoffmann U, Bamberg F, Chae CU, Nichols JH, Rogers IS, Seneviratne SK, et-al..
Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial..
J Am Coll Cardiol. , 53 (2009), pp. 1642-1650
[38]
Rubinshtein R, Halon DA, Gaspar T, Jaffe R, Karkabi B, Flugelman MY, et-al..
Usefulness of 64-slice cardiac computed tomographic angiography for diagnosing acute coronary syndromes and predicting clinical outcome in emergency department patients with chest pain of uncertain origin..
Circulation. , 115 (2007), pp. 1762-1768
[39]
Meijboom WB, Mollet NR, Van Mieghem CA, Weustink AC, Pugliese F, Van Pelt N, et-al..
64-Slice CT coronary angiography in patients with non-ST elevation acute coronary syndrome..
Heart. , 93 (2007), pp. 1386-1392
[40]
Hollander JE, Chang AM, Shofer FS, Collin MJ, Walsh KM, McCusker CM, et-al..
Oneyear outcomes following coronary computerized tomographic angiography for evaluation of emergency department patients with potential acute coronary syndrome..
Acad Emerg Med. , 16 (2009), pp. 693-698
[41]
Chang SA, Choi SI, Choi EK, Kim HK, Jung JW, Chun EJ, et-al..
Usefulness of 64-slice multidetector computed tomography as an initial diagnostic approach in patients with acute chest pain..
Am Heart J. , 156 (2008), pp. 375-383
[42]
Effects of tissue plasminogen activator, a comparison of early invasive, conservative strategies in unstable angina, non-Q-wave myocardial infarction..
Results of the TIMI IIIB Trial..
Thrombolysis in Myocardial Ischemia. Circulation. , 89 (1994), pp. 1545-1556
[43]
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999; 354:708-15..
[44]
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, Van’ t Veer M, et-al..
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention..
N Engl J Med. , 360 (2009), pp. 213-224
[45]
Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et-al..
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial..
Lancet. , 377 (2011), pp. 1409-1420
[46]
Hasdai D, Lev EI, Behar S, Boyko V, Danchin N, Vahanian A, et-al..
Acute coronary syndromes in patients with pre-existing moderate to severe valvular disease of the heart: lessons from the Euro-Heart Survey of acute coronary syndromes..
Eur Heart J. , 24 (2003), pp. 623-629
[47]
Hasin Y, Danchin N, Filippatos GS, Heras M, Janssens U, Leor J, et-al..
Recommendations for the structure, organization, and operation of intensive cardiac care units..
Eur Heart J. , 26 (2005), pp. 1676-1682
[48]
Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et-al..
Predictors of hospital mortality in the global registry of acute coronary events..
Arch Intern Med. , 163 (2003), pp. 2345-2353
[49]
Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et-al..
The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making..
JAMA. , 284 (2000), pp. 835-842
[50]
Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et-al..
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)..
[51]
Carrillo X, Curos A, Muga R, Serra J, Sanvisens A, Bayes-Genis A..
Acute coronary syndrome and cocaine use: 8-year prevalence and inhospital outcomes..
Eur Heart J. , 32 (2011), pp. 1244-1250
[52]
Holmvang L, Clemmensen P, Lindahl B, Lagerqvist B, Venge P, Wagner G, et-al..
Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment..
J Am Coll Cardiol. , 41 (2003), pp. 905-915
[53]
Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, et-al..
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb..
PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. J Am Coll Cardiol. , 38 (2001), pp. 64-71
[54]
Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E..
Risk stratification by early exercise testing after an episode of unstable coronary artery disease..
The RISC Study Group. Int J Cardiol. , 39 (1993), pp. 131-142
[55]
Amsterdam EA, Kirk JD, Diercks DB, Lewis WR, Turnipseed SD..
Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain..
J Am Coll Cardiol. , 40 (2002), pp. 251-256
[56]
Scirica BM, Morrow DA, Budaj A, Dalby AJ, Mohanavelu S, Qin J, et-al..
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial..
J Am Coll Cardiol. , 53 (2009), pp. 1411-1421
[57]
Akkerhuis KM, Klootwijk PA, Lindeboom W, Umans VA, Meij S, Kint PP, et-al..
Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients..
Eur Heart J. , 22 (2001), pp. 1997-2006
[58]
Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et-al..
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes..
N Engl J Med. , 335 (1996), pp. 1342-1349
[59]
Kontos MC, De Lemos JA, Ou FS, Wiviott SD, Foody JM, Newby LK, et-al..
Troponinpositive..
MB-negative patients with non-ST-elevation myocardial infarction: an undertreated but high-risk patient group: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network—Get With The Guidelines (NCDR ACTION-GWTG) Registry. Am Heart J. , 160 (2010), pp. 819-825
[60]
James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et-al..
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy..
Circulation. , 108 (2003), pp. 275-281
[61]
Steg PG, FitzGerald G, Fox KA..
Risk stratification in non-ST-segment elevation acute coronary syndromes: troponin alone is not enough..
Am J Med. , 122 (2009), pp. 107-108
[62]
Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et-al..
Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care..
Eur Heart J. , (2011), pp. 10
[63]
Heeschen C, Hamm CW, Bruemmer J, Simoons ML..
Predictive value of Creactive protein and troponin T in patients with unstable angina: a comparative analysis..
CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. , 35 (2000), pp. 1535-1542
[64]
Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et-al..
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy..
Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. , 31 (1998), pp. 1460-1465
[65]
Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L..
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease..
FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. , 343 (2000), pp. 1139-1147
[66]
Currie CJ, Poole CD, Conway P..
Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality..
Heart. , 94 (2008), pp. 457-462
[67]
Aronson D, Hammerman H, Suleiman M, Markiewicz W..
Usefulness of changes in fasting glucose during hospitalization to predict long-term mortality in patients with acute myocardial infarction..
Am J Cardiol. , 104 (2009), pp. 1013-1017
[68]
Suleiman M, Hammerman H, Boulos M, Kapeliovich MR, Suleiman A, Agmon Y, et-al..
Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study..
Circulation. , 111 (2005), pp. 754-760
[69]
Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et-al..
Association of hemoglobin levels with clinical outcomes in acute coronary syndromes..
Circulation. , 111 (2005), pp. 2042-2049
[70]
Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, et-al..
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial..
J Gen Intern Med. , 23 (2008), pp. 310-316
[71]
Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, et-al..
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes..
Circulation. , 106 (2002), pp. 974-980
[72]
Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et-al..
Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes..
Circulation. , 108 (2003), pp. 1440-1445
[73]
Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et-al..
Prognostic value of myeloperoxidase in patients with chest pain..
N Engl J Med. , 349 (2003), pp. 1595-1604
[74]
Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, et-al..
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome..
Circulation. , 115 (2007), pp. 962-971
[75]
Morrow DA, Sabatine MS, Brennan ML, De Lemos JA, Murphy SA, Ruff CT, et-al..
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18..
Eur Heart J. , 29 (2008), pp. 1096-1102
[76]
Viswanathan K, Kilcullen N, Morrell C, Thistlethwaite SJ, Sivananthan MU, Hassan TB, et-al..
Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative..
J Am Coll Cardiol. , 55 (2010), pp. 2590-2598
[77]
Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G..
Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction..
The French Nationwide OPERA study. Am Heart J. , 159 (2010), pp. 570-576
[78]
Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et-al..
Incremental value of copeptin for rapid rule out of acute myocardial infarction..
J Am Coll Cardiol. , 54 (2009), pp. 60-68
[79]
De Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R..
TIMI..
PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. , 26 (2005), pp. 865-872
[80]
Aragam KG, Tamhane UU, Kline-Rogers E, Li J, Fox KA, Goodman SG, et-al..
Does simplicity compromise accuracy in ACS risk prediction?. A retrospective analysis of the TIMI and GRACE risk scores..
[81]
Eggers KM, Kempf T, Venge P, Wallentin L, Wollert KC, Lindahl B..
Improving longterm risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers..
Am Heart J. , 160 (2010), pp. 88-94
[82]
Khot UN, Jia G, Moliterno DJ, Lincoff AM, Khot MB, Harrington RA, et-al..
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification..
JAMA. , 290 (2003), pp. 2174-2181
[83]
Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et-al..
Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score..
Circulation. , 119 (2009), pp. 1873-1882
[84]
Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et-al..
A risk score to predict bleeding in patients with acute coronary syndromes..
J Am Coll Cardiol. , 55 (2010), pp. 2556-2566
[85]
Yusuf S, Peto R, Lewis J, Collins R, Sleight P..
Beta blockade during and after myocardial infarction: an overview of the randomized trials..
Prog Cardiovasc Dis. , 27 (1985), pp. 335-371
[86]
Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1..
First International Study of Infarct Survival Collaborative Group..
Lancet. , 2 (1986), pp. 57-66
[87]
Telford AM, Wilson C..
Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome..
Lancet. , 1 (1981), pp. 1225-1228
[88]
Lubsen J, Tijssen JG..
Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT)..
Am J Cardiol. , 60 (1987), pp. 18A-25A
[89]
Yusuf S, Wittes J, Friedman L..
Overview of results of randomized clinical trials in heart disease..
I. Treatments following myocardial infarction. JAMA. , 260 (1988), pp. 2088-2093
[90]
Metoprolol in acute myocardial infarction (MIAMI)..
A randomised placebocontrolled international trial..
The MIAMI Trial Research Group. Eur Heart J. , 6 (1985), pp. 199-226
[91]
Miller CD, Roe MT, Mulgund J, Hoekstra JW, Santos R, Pollack CV, et-al..
Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction..
Am J Med. , 120 (2007), pp. 685-692
[92]
Brandler E, Paladino L, Sinert R..
Does the early administration of beta-blockers improve the in-hospital mortality rate of patients admitted with acute coronary syndrome?..
Acad Emerg Med. , 17 (2010), pp. 1-10
[93]
Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et-al..
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial..
Lancet. , 366 (2005), pp. 1622-1632
[94]
Borzak S, Cannon CP, Kraft PL, Douthat L, Becker RC, Palmeri ST, et-al..
Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina..
TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol. , 81 (1998), pp. 678-681
[95]
Ambrosio G, Del Pinto M, Tritto I, Agnelli G, Bentivoglio M, Zuchi C, et-al..
Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events..
Eur Heart J. , 31 (2010), pp. 430-438
[96]
Cotter G, Faibel H, Barash P, Shemesh E, Moshkovitz Y, Metzkor E, et-al..
High-dose nitrates in the immediate management of unstable angina: optimal dosage, route of administration, and therapeutic goals..
Am J Emerg Med. , 16 (1998), pp. 219-224
[97]
Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD..
A randomized study comparing propranolol and diltiazem in the treatment of unstable angina..
J Am Coll Cardiol. , 5 (1985), pp. 717-722
[98]
Parodi O, Simonetti I, Michelassi C, Carpeggiani C, Biagini A, L’Abbate A, et-al..
Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit..
Am J Cardiol. , 57 (1986), pp. 899-906
[99]
Hansen JF..
Treatment with verapamil after an acute myocardial infarction..
Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II). Drugs. , 42 (1991), pp. 43-53
[100]
Moss AJ, Oakes D, Rubison M, McDermott M, Carleen E, Eberly S, et-al..
Effects of diltiazem on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension..
The Multicenter Diltiazem Postinfarction Trial Research Group. Am J Cardiol. , 68 (1991), pp. 429-433
[101]
Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002; 359:1269-75..
[102]
Borer JS..
Therapeutic effects of I(f) blockade: evidence and perspective..
Pharmacol Res. , 53 (2006), pp. 440-445
[103]
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et-al..
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial..
JAMA. , 297 (2007), pp. 1775-1783
[104]
Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, et-al..
Aspirin, heparin, or both to treat acute unstable angina..
N Engl J Med. , 319 (1988), pp. 1105-1111
[105]
Theroux P, Waters D, Qiu S, McCans J, De Guise P, Juneau M..
Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina..
Circulation. , 88 (1993), pp. 2045-2048
[106]
Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et-al..
Aspirin, sulfinpyrazone, or both in unstable angina..
Results of a Canadian multicenter trial. N Engl J Med. , 313 (1985), pp. 1369-1375
[107]
Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et-al..
Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials..
Lancet. , 373 (2009), pp. 1849-1860
[108]
Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et-al..
Doubledose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial..
Lancet. , 376 (2010), pp. 1233-1243
[109]
Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et-al..
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction..
Circulation. , 113 (2006), pp. 2906-2913
[110]
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK..
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation..
N Engl J Med. , 345 (2001), pp. 494-502
[111]
Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, et-al..
Early and late effects of clopidogrel in patients with acute coronary syndromes..
Circulation. , 107 (2003), pp. 966-972
[112]
Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, et-al..
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome..
JAMA. , 299 (2008), pp. 532-539
[113]
Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et-al..
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial..
Circulation. , 110 (2004), pp. 1202-1208
[114]
Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, et-al..
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation..
Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol. , 48 (2006), pp. 931-938
[115]
Snoep JD, Hovens MM, Eikenboom JC, Van der Bom JG, Jukema JW, Huisman MV..
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis..
Am Heart J. , 154 (2007), pp. 221-231
[116]
Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet J-P, Montalescot G, et-al..
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study..
JACC Cardiovasc Interv. , 1 (2008), pp. 631-638
[117]
The CURRENT-OASIS, 7, Investigators..
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes..
N Engl J Med. , 363 (2010), pp. 930-942
[118]
Taubert D, Von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et-al..
Impact of P-glycoprotein on clopidogrel absorption..
Clin Pharmacol Ther. , 80 (2006), pp. 486-501
[119]
Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, et-al..
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis..
Lancet. , 376 (2010), pp. 1312-1319
[120]
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et-al..
Reducedfunction CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis..
JAMA. , 304 (2010), pp. 1821-1830
[121]
Breet N, Van Werkum J, Bouman H, Kelder J, Ruven H, Bal E, et-al..
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation..
JAMA. , 303 (2010), pp. 754-762
[122]
Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, et-al..
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation..
Eur Heart J. , 27 (2006), pp. 2420-2425
[123]
Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et-al..
Cytochrome P450 2C19 681G.A. polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents..
J Am Coll Cardiol. , 51 (2008), pp. 1925-1934
[124]
Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et-al..
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial..
JAMA. , 305 (2011), pp. 1097-1105
[125]
O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et-al..
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials..
Lancet. , 374 (2009), pp. 989-997
[126]
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et-al..
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents..
Circulation. , 122 (2010), pp. 2619-2633
[127]
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et-al..
Clopidogrel with or without omeprazole in coronary artery disease..
N Engl J Med. , 363 (2010), pp. 1909-1917
[128]
Wiviott SD, Trenk D, Frelinger AL, O’Donoghue M, Neumann F-J, Michelson AD, et-al..
PRINCIPLE-TIMI 44 Investigators..
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial. Circulation. , 116 (2007), pp. 2923-2932
[129]
Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et-al..
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel..
J Clin Pharmacol. , 48 (2008), pp. 475-484
[130]
Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S, et-al..
Prasugrel versus clopidogrel in patients with acute coronary syndromes..
N Engl J Med. , 357 (2007), pp. 2001-2015
[131]
Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et-al..
Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study..
Circulation. , 120 (2009), pp. 2577-2585
[132]
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et-al..
en representación de PLATO Investigators..
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. , 361 (2009), pp. 1045-1057
[133]
Cannon C, Harrington R, James S, Ardissino D, Becker R, Emanuelsson H, et-al..
the PLATelet inhibition and patient Outcomes (PLATO) investigators..
Ticagrelor compared with clopidogrel in acute coronary syndromes patients with a planned invasive strategy (PLATO): a randomised double-blind study. Lancet. , 375 (2010), pp. 283-293
[134]
Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et-al..
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery results from the PLATO (Platelet Inhibition and Patient Outcomes) Trial..
J Am Coll Cardiol. , 57 (2011), pp. 672-684
[135]
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G..
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin..
Eur Heart J. , 27 (2006), pp. 1038-1047
[136]
Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, et-al..
Safety, tolerability, and initial efficacy of AZD6140, the First reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 Trial..
J Am Coll Cardiol. , 50 (2007), pp. 1844-1851
[137]
Storey RF, Bliden K, Patil SB, Karunakaran A, Ecob R, Butler K, et-al..
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET/OFFSET Study..
J Am Coll Cardiol. , 56 (2010), pp. 185-193
[138]
Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC..
Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis..
J Am Coll Cardiol. , 52 (2008), pp. 1693-1701
[139]
Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MK, et-al..
Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?..
Eur Heart J. , 26 (2005), pp. 576-583
[140]
Mehta RH, Roe MT, Mulgund J, Ohman EM, Cannon CP, Gibler WB, et-al..
Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery..
J Am Coll Cardiol. , 48 (2006), pp. 281-286
[141]
Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, et-al..
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial..
J Am Coll Cardiol. , 53 (2009), pp. 1965-1972
[142]
Kim JH, Newby LK, Clare RM, Shaw LK, Lodge AJ, Smith PK, et-al..
Clopidogrel use and bleeding after coronary artery bypass graft surgery..
Am Heart J. , 156 (2008), pp. 886-892
[143]
Fitchett D, Eikelboom J, Fremes S, Mazer D, Singh S, Bittira B, et-al..
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society..
Can J Cardiol. , 25 (2009), pp. 683-689
[144]
Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, et-al..
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes..
Circulation. , 110 (2004), pp. 2361-2367
[145]
Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, et-al..
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions..
American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. , 115 (2007), pp. 813-818
[146]
Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et-al..
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study..
Lancet. , 358 (2001), pp. 527-533
[147]
Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C, et-al..
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial..
JAMA. , 288 (2002), pp. 2411-2420
[148]
Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et-al..
Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)..
Eur Heart J. , 31 (2010), pp. 2501-2555
[149]
Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et-al..
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes..
Gradient of benefit related to the revascularisation strategy. Eur Heart J. , 23 (2002), pp. 1441-1448
[150]
Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, et-al..
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial..
JAMA. , 297 (2007), pp. 591-602
[151]
Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, et-al..
the EARLY ACS Investigators..
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. , 360 (2009), pp. 2176-2190
[152]
Kastrati A, Mehilli J, Neumann F-J, Dotzer F, Ten Berg J, Bollwein H, et al, for the Intracoronary Stenting, Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 Trial I..
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 Randomized Trial..
JAMA. , 295 (2006), pp. 1531-1538
[153]
Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ..
Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis..
Am Heart J. , 140 (2000), pp. 206-211
[154]
Jubelirer SJ, Koenig BA, Bates MC..
Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy..
Am J Hematol. , 61 (1999), pp. 205-208
[155]
Lajus S, Clofent-Sanchez G, Jais C, Coste P, Nurden P, Nurden AT..
Thrombocytopenia after abciximab use results from different mechanisms..
Thromb Haemost. , 103 (2010), pp. 651-661
[156]
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998; 339:436-43..
[157]
Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, et-al..
Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting..
Circulation. , 109 (2004), pp. 2203-2206
[158]
Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et-al..
the TARGET Investigators..
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. , 344 (2001), pp. 1888-1894
[159]
Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, et-al..
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study..
Lancet. , 360 (2002), pp. 355-360
[160]
De Luca G, Ucci G, Cassetti E, Marino P..
Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a metaanalysis..
J Am Coll Cardiol. , 53 (2009), pp. 1668-1673
[161]
Valgimigli M, Biondi-Zoccai G, Tebaldi M, Van’t Hof AWJ, Campo G, Hamm C, et-al..
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials..
Eur Heart J. , 31 (2010), pp. 35-49
[162]
O’Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, et-al..
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis..
J Am Coll Cardiol. , 54 (2009), pp. 678-685
[163]
Buller C, Pate G, Armstrong P, O’Neill B, Webb J, Gallo R, et-al..
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment..
Can J Cardiol. , 22 (2006), pp. 511-515
[164]
Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, et-al..
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial..
J Am Coll Cardiol. , 54 (2009), pp. 468-476
[165]
White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, et-al..
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial..
J Am Coll Cardiol. , 52 (2008), pp. 807-814
[166]
Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV, Feit F, et-al..
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial..
JACC Cardiovasc Interv. , 1 (2008), pp. 639-648
[167]
Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly B, Granger CB, et-al..
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention..
The Global Registry of Acute Coronary Events (GRACE). Am Heart J. , 153 (2007), pp. 960-969
[168]
Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, et al, for the CRUSADE, Investigators..
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes..
JAMA. , 294 (2005), pp. 3108-3116
[169]
Li Y, Spencer F, Becker R..
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition..
Am Heart J. , 143 (2002), pp. 725-732
[170]
Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, et-al..
Evaluation of prolonged antithrombotic pretreatment (‘cooling-off’ strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial..
JAMA. , 290 (2003), pp. 1593-1599
[171]
Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, et-al..
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)..
Chest. , 133 (2008), pp. S670-S707
[172]
Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S..
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis..
Lancet. , 355 (2000), pp. 1936-1942
[173]
Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, et-al..
PENTUA Investigators. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol. , 43 (2004), pp. 2183-2190
[174]
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et-al..
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial..
JAMA. , 295 (2006), pp. 1519-1530
[175]
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et-al..
Comparison of fondaparinux and enoxaparin in acute coronary syndromes..
N Engl J Med. , 354 (2006), pp. 1464-1476
[176]
Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, et-al..
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) pilot trial..
Circulation. , 111 (2005), pp. 1390-1397
[177]
Anderson JA, Hirsh J, Yusuf S, Johnston M, Afzal R, Mehta SR, et-al..
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial..
J Thromb Haemost. , 8 (2010), pp. 243-249
[178]
Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, et-al..
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial..
JAMA. , 304 (2010), pp. 1339-1349
[179]
Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et-al..
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction..
Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. , 100 (1999), pp. 1593-1601
[180]
Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et-al..
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group..
N Engl J Med. , 337 (1997), pp. 447-452
[181]
FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronaryartery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701-7..
[182]
Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lowmolecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561-8..
[183]
Hirsh J, Raschke R..
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy..
Chest. , 126 (2004), pp. S188-S203
[184]
TIMI 11A Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol. 1997; 29:1474-82..
[185]
Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, et-al..
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin..
Circulation. , 110 (2004), pp. 392-398
[186]
Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, et-al..
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention..
J Am Coll Cardiol. , 40 (2002), pp. 1943-1950
[187]
Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, et-al..
Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris..
Circulation. , 103 (2001), pp. 658-663
[188]
Murphy S, Gibson C, Morrow D, Van de Werf F, Menown I, Goodman S, et-al..
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis..
Eur Heart J. , 28 (2007), pp. 2077-2086
[189]
Blazing MA, De Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, et-al..
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial..
JAMA. , 292 (2004), pp. 55-64
[190]
Cohen M, Theroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, et-al..
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study..
The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J. , 144 (2002), pp. 470-477
[191]
Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A..
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in highrisk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide..
Circulation. , 107 (2003), pp. 238-244
[192]
Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et-al..
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial..
JAMA. , 292 (2004), pp. 45-54
[193]
Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, et-al..
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview..
JAMA. , 292 (2004), pp. 89-96
[194]
Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, et-al..
Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis..
Br J Clin Pharmacol. , 60 (2005), pp. 364-373
[195]
Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et-al..
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention..
N Engl J Med. , 355 (2006), pp. 1006-1017
[196]
Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et-al..
ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. , 355 (2006), pp. 2203-2216
[197]
Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et-al..
Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators..
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. , 369 (2007), pp. 907-919
[198]
Stone G, Ware J, Bertrand M, Lincoff A, Moses J, Ohman E, et al, en representación de ACUITY, Investigators..
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial..
JAMA. , 298 (2007), pp. 2497-2506
[199]
White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV, Feit F, et-al..
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial..
J Am Coll Cardiol. , 51 (2008), pp. 1734-1741
[200]
Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et-al..
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial..
Circulation. , 119 (2009), pp. 2877-2885
[201]
Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et-al..
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial..
[202]
Alexander J, Becker R, Bhatt D, Cools F, Crea F, Dellborg M, et-al..
For the APPRAISE Steering Committee and Investigators..
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. , 119 (2009), pp. 2877-2885
[203]
Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, et-al..
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial..
Lancet. , 374 (2009), pp. 787-795
[204]
Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, et-al..
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)..
Eur Heart J. , 31 (2010), pp. 1311-1318
[205]
Yan AT, Yan RT, Tan M, Eagle KA, Granger CB, Dabbous OH, et-al..
In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score..
Am J Cardiol. , 96 (2005), pp. 913-916
[206]
Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, et-al..
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials..
JAMA. , 293 (2005), pp. 2908-2917
[207]
Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT..
Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials..
J Am Coll Cardiol. , 48 (2006), pp. 1319-1325
[208]
O’Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, De Winter RJ, et-al..
Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a metaanalysis..
JAMA. , 300 (2008), pp. 71-80
[209]
Fox KA, Clayton TC, Damman P, Pocock SJ, De Winter RJ, Tijssen JG, et-al..
Longterm outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data..
J Am Coll Cardiol. , 55 (2010), pp. 2435-2445
[210]
Montalescot G, Cayla G, Collet JP, Elhadad S, Beygui F, Le Breton H, et-al..
Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial..
JAMA. , 302 (2009), pp. 947-954
[211]
Van’t Hof AW, De Vries ST, Dambrink JH, Miedema K, Suryapranata H, et-al..
A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study..
2b/3a upstream therapy and acute coronary syndromes. Eur Heart J. , 24 (2003), pp. 1401-1405
[212]
Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, et-al..
Early versus delayed invasive intervention in acute coronary syndromes..
N Engl J Med. , 360 (2009), pp. 2165-2175
[213]
Katritsis DG, Siontis GC, Kastrati A, Van’t Hof AW, Neumann FJ, Siontis KC, et-al..
Optimal timing of coronary angiography and potential intervention in non-STelevation acute coronary syndromes..
Eur Heart J. , 32 (2010), pp. 32-40
[214]
Riezebos RK, Ronner E, Ter Bals E, Slagboom T, Smits PC, Ten Berg JM, et-al..
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes..
Heart. , 95 (2009), pp. 807-812
[215]
Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, et-al..
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial..
J Am Coll Cardiol. , 55 (2010), pp. 1416-1424
[216]
Brener SJ, Milford-Beland S, Roe MT, Bhatt DL, Weintraub WS, Brindis RG..
Culpritonly or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report..
Am Heart J. , 155 (2008), pp. 140-146
[217]
Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, et-al..
Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial..
JACC Cardiovasc Interv. , 3 (2010), pp. 1059-1067
[218]
Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et-al..
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease..
N Engl J Med. , 360 (2009), pp. 961-972
[219]
Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et-al..
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease..
EuroIntervention. , 1 (2005), pp. 219-227
[220]
De Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et-al..
Early invasive versus selectively invasive management for acute coronary syndromes..
N Engl J Med. , 353 (2005), pp. 1095-1104
[221]
Monteiro P..
Impact of early coronary artery bypass graft in an unselected acute coronary syndrome patient population..
Circulation. , 114 (2006), pp. I467-I472
[222]
Parikh SV, De Lemos JA, Jessen ME, Brilakis ES, Ohman EM, Chen AY, et-al..
Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines)..
JACC Cardiovasc Interv. , 3 (2010), pp. 419-427
[223]
Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA..
Does clopidogrel increase blood loss following coronary artery bypass surgery?..
Ann Thorac Surg. , 78 (2004), pp. 1536-1541
[224]
Solodky A, Behar S, Boyko V, Battler A, Hasdai D..
The outcome of coronary artery bypass grafting surgery among patients hospitalized with acute coronary syndrome: the Euro Heart Survey of acute coronary syndrome experience..
Cardiology. , 103 (2005), pp. 44-47
[225]
Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et-al..
Drug-eluting versus bare-metal stents in large coronary arteries..
N Engl J Med. , 363 (2010), pp. 2310-2319
[226]
Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A..
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes..
Cochrane Database Syst Rev. , (2010), pp. CD004587
[227]
Vlaar PJ, Diercks GF, Svilaas T, Vogelzang M, De Smet BJ, Van den Heuvel AF, et-al..
The feasibility and safety of routine thrombus aspiration in patients with non-STelevation myocardial infarction..
Catheter Cardiovasc Interv. , 72 (2008), pp. 937-942
[228]
Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, et-al..
Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey..
Eur Heart J. , 27 (2006), pp. 789-795
[229]
Bauer T, Koeth O, Junger C, Heer T, Wienbergen H, Gitt A, et-al..
Effect of an invasive strategy on in-hospital outcome in elderly patients with non-ST-elevation myocardial infarction..
Eur Heart J. , 28 (2007), pp. 2873-2878
[230]
Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, et-al..
Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology..
Circulation. , 115 (2007), pp. 2549-2569
[231]
Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, et-al..
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-STsegment elevation acute coronary syndromes..
JAMA. , 294 (2005), pp. 3108-3116
[232]
Lopes RD, Alexander KP, Marcucci G, White HD, Spinler S, Col J, et-al..
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial..
Eur Heart J. , 29 (2008), pp. 1827-1833
[233]
Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E..
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronaryartery disease: the FRISC II invasive randomised trial..
FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. , 356 (2000), pp. 9-16
[234]
Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E, allentin WL..
5-Year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study..
Lancet. , 368 (2006), pp. 998-1004
[235]
Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, et-al..
The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes..
Ann Intern Med. , 141 (2004), pp. 186-195
[236]
Rosengren A, Wallentin L, Gitt AK, Behar S, Battler A, Hasdai D..
Sex, age, and clinical presentation of acute coronary syndromes..
Eur Heart J. , 25 (2004), pp. 663-670
[237]
Alfredsson J, Stenestrand U, Wallentin L, Swahn E..
Gender differences in management and outcome in non-ST-elevation acute coronary syndrome..
Heart. , 93 (2007), pp. 1357-1362
[238]
Hvelplund A, Galatius S, Madsen M, Rasmussen JN, Rasmussen S, Madsen JK, et-al..
Women with acute coronary syndrome are less invasively examined and subsequently less treated than men..
Eur Heart J. , 31 (2010), pp. 684-690
[239]
Diercks DB, Owen KP, Kontos MC, Blomkalns A, Chen AY, Miller C, et al. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J. 2010;160:80-87.e83..
[240]
Heer T, Gitt AK, Juenger C, Schiele R, Wienbergen H, Towae F, et-al..
Gender differences in acute non-ST-segment elevation myocardial infarction..
Am J Cardiol. , 98 (2006), pp. 160-166
[241]
Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM..
Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature..
Am J Cardiol. , 93 (2004), pp. 830-835
[242]
Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et-al..
Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial..
Randomized Intervention Trial of unstable Angina. Lancet. , 360 (2002), pp. 743-751
[243]
Hoenig MR, Doust JA, Aroney CN, Scott IA..
Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era..
Cochrane Database Syst Rev. , (2006), pp. CD004815
[244]
Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, et-al..
Benefit of an early invasive management strategy in women with acute coronary syndromes..
JAMA. , 288 (2002), pp. 3124-3129
[245]
Boersma E, Harrington RA, Moliterno DJ, White H, Simoons ML..
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes..
Lancet. , 360 (2002), pp. 342-343
[246]
Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, et-al..
Sex differences in mortality following acute coronary syndromes..
JAMA. , 302 (2009), pp. 874-882
[247]
Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L..
Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction..
Eur Heart J. , 25 (2004), pp. 1990-1997
[248]
Dotevall A, Hasdai D, Wallentin L, Battler A, Rosengren A..
Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes..
Data from the Euro Heart Survey ACS. Diabet Med. , 22 (2005), pp. 1542-1550
[249]
Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et-al..
Diabetes and mortality following acute coronary syndromes..
JAMA. , 298 (2007), pp. 765-775
[250]
Hasin T, Hochadel M, Gitt AK, Behar S, Bueno H, Hasin Y..
Comparison of treatment and outcome of acute coronary syndrome in patients with versus patients without diabetes mellitus..
Am J Cardiol. , 103 (2009), pp. 772-778
[251]
De Caterina R, Madonna R, Sourij H, Wascher T..
Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options..
Eur Heart J. , 31 (2010), pp. 1557-1564
[252]
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et-al..
European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)..
Eur Heart J. , 28 (2007), pp. 2375-2414
[253]
Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et-al..
Intensive versus conventional glucose control in critically ill patients..
N Engl J Med. , 360 (2009), pp. 1283-1297
[254]
Diaz R, Goyal A, Mehta SR, Afzal R, Xavier D, Pais P, et-al..
Glucose-insulinpotassium therapy in patients with ST-segment elevation myocardial infarction..
JAMA. , 298 (2007), pp. 2399-2405
[255]
Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et-al..
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban..
N Engl J Med. , 344 (2001), pp. 1879-1887
[256]
Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et-al..
Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials..
Lancet. , 373 (2009), pp. 1190-1197
[257]
Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et-al..
The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction..
Circulation. , 120 (2009), pp. 2529-2540
[258]
Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et-al..
A randomized trial of therapies for type 2 diabetes and coronary artery disease..
N Engl J Med. , 360 (2009), pp. 2503-2515
[259]
Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, et-al..
Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents..
J Am Coll Cardiol. , 55 (2010), pp. 1067-1075
[260]
Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et-al..
Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease..
N Engl J Med. , 358 (2008), pp. 331-341
[261]
Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, et-al..
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis..
BMJ. , 337 (2008), pp. a1331
[262]
Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et-al..
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38..
Circulation. , 118 (2008), pp. 1626-1636
[263]
James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, et-al..
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial..
Eur Heart J. , 31 (2010), pp. 3006-3016
[264]
Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, et-al..
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non ST-segment-elevation acute coronary syndromes..
Circulation. , 104 (2001), pp. 2767-2771
[265]
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE..
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus..
Cochrane Database Syst Rev. , (2010), pp. CD002967
[266]
Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et-al..
A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS)..
Eur Heart J. , 23 (2002), pp. 1190-1201
[267]
Goldenberg I, Subirana I, Boyko V, Vila J, Elosua R, Permanyer-Miralda G, et-al..
Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome Research and Indicators Collection Project..
Arch Intern Med. , 170 (2010), pp. 888-895
[268]
Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, et-al..
Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register..
J Intern Med. , 268 (2010), pp. 40-49
[269]
Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, Lopez-Sendon J, et-al..
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes..
The Global Registry of Acute Coronary Events. Eur Heart J. , 26 (2005), pp. 2285-2293
[270]
Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, et-al..
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes..
Ann Intern Med. , 147 (2007), pp. 304-310
[271]
James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et-al..
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial..
Circulation. , 122 (2010), pp. 1056-1067
[272]
Pannu N, Wiebe N, Tonelli M..
Prophylaxis strategies for contrast-induced nephropathy..
JAMA. , 295 (2006), pp. 2765-2779
[273]
Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, et-al..
Influence of renal function on the effects of early revascularization in non-STelevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)..
Circulation. , 120 (2009), pp. 851-858
[274]
Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lopez-Sendon J, et-al..
Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE)..
Circulation. , 109 (2004), pp. 494-499
[275]
Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, et-al..
2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy..
Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. , 31 (2010), pp. 2677-2687
[276]
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et-al..
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction..
N Engl J Med. , 348 (2003), pp. 1309-1321
[277]
Zannad F, McMurray JJ, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, et-al..
Eplerenone in patients with systolic heart failure and mild symptoms..
N Engl J Med. , 364 (2011), pp. 11-21
[278]
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et-al..
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction..
N Engl J Med. , 346 (2002), pp. 877-883
[279]
Diercks DB, Roe MT, Mulgund J, Pollack CV, Kirk JD, Gibler WB, et-al..
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative..
Am Heart J. , 152 (2006), pp. 140-148
[280]
Steinberg BA, Cannon CP, Hernandez AF, Pan W, Peterson ED, Fonarow GC..
Medical therapies and invasive treatments for coronary artery disease by body mass: the ‘obesity paradox’ in the Get With The Guidelines database..
Am J Cardiol. , 100 (2007), pp. 1331-1335
[281]
Ong P, Athanasiadis A, Borgulya G, Voehringer M, echtem SU..
3-Year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) study follow-up..
J Am Coll Cardiol. , 57 (2011), pp. 147-152
[282]
Hasin T, Sorkin A, Markiewicz W, Hammerman H, Aronson D..
Prevalence and prognostic significance of transient, persistent, and new-onset anemia after acute myocardial infarction..
Am J Cardiol. , 104 (2009), pp. 486-491
[283]
Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, et-al..
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes..
Eur Heart J. , 31 (2010), pp. 50-58
[284]
Chase AJ, Fretz EB, Warburton WP, Klinke WP, Carere RG, Pi D, et-al..
Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L. study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg)..
Heart. , 94 (2008), pp. 1019-1025
[285]
Agostoni P, Biondi-Zoccai GG, De Benedictis ML, Rigattieri S, Turri M, Anselmi M, et-al..
Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; systematic overview and meta-analysis of randomized trials..
J Am Coll Cardiol. , 44 (2004), pp. 349-356
[286]
Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM, et-al..
Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes..
Am Heart J. , 155 (2008), pp. 1047-1053
[287]
Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland DB, et-al..
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion..
Cochrane Database Syst Rev. , (2002), pp. CD002042
[288]
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et-al..
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium (BARC)..
Circulation. , 123 (2011), pp. 2736-2747
[289]
Fox KA, Carruthers K, Steg PG, Avezum A, Granger CB, Montalescot G, et-al..
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome?..
The global registry of acute coronary events. Eur Heart J. , 31 (2010), pp. 667-675
[290]
Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S..
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes..
Circulation. , 114 (2006), pp. 774-782
[291]
Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand JP, et-al..
Improving clinical outcomes by reducing bleeding in patients with non-STelevation acute coronary syndromes..
Eur Heart J. , 30 (2009), pp. 655-661
[292]
Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, et-al..
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial..
Eur Heart J. , 30 (2009), pp. 1457-1466
[293]
Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, et-al..
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis..
J Am Coll Cardiol. , 51 (2008), pp. 2028-2033
[294]
Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, et-al..
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization..
Management, and Avoidance (CHARISMA) trial. Circulation. , 121 (2010), pp. 2575-2583
[295]
Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, et-al..
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data..
Lancet. , 374 (2009), pp. 1967-1974
[296]
Joyner CD, Peters RJ, Afzal R, Chrolavicius S, Mehta SR, Fox KA, et-al..
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk..
Am Heart J. , 157 (2009), pp. 502-508
[297]
Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, et-al..
Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?..
Circulation. , 116 (2007), pp. 2793-2801
[298]
Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et-al..
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes..
JAMA. , 292 (2004), pp. 1555-1562
[299]
Alexander KP, Peterson ED..
Minimizing the risks of anticoagulants and platelet inhibitors..
Circulation. , 121 (2010), pp. 1960-1970
[300]
Marso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, et-al..
Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention..
JAMA. , 303 (2010), pp. 2156-2164
[301]
Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et-al..
Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications..
Ann Intern Med. , 154 (2011), pp. 529-540
[302]
Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et-al..
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care..
Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. , 340 (1999), pp. 409-417
[303]
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et-al..
Correction of anemia with epoetin alfa in chronic kidney disease..
N Engl J Med. , 355 (2006), pp. 2085-2098
[304]
Menzin J, Wygant G, Hauch O, Jackel J, Friedman M..
One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database..
Curr Med Res Opin. , 24 (2008), pp. 461-468
[305]
Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et-al..
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart..
Lung, and Blood Institute. Circulation. , 113 (2006), pp. 2363-2372
[306]
Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S..
Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes..
Circulation. , 121 (2010), pp. 750-758
[307]
Chew DP, Huynh LT, Liew D, Astley C, Soman A, Brieger D..
Potential survival gains in the treatment of myocardial infarction..
Heart. , 95 (2009), pp. 1844-1850
[308]
Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et-al..
Explaining the decrease in U.S. deaths from coronary disease, 1980-2000..
N Engl J Med. , 356 (2007), pp. 2388-2398
[309]
Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S..
Angiotensinconvertingenzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials..
Lancet. , 368 (2006), pp. 581-588
[310]
Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG..
Angiotensinconverting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials..
Arch Intern Med. , 166 (2006), pp. 787-796
[311]
Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et-al..
Telmisartan, ramipril, or both in patients at high risk for vascular events..
N Engl J Med. , 358 (2008), pp. 1547-1559
[312]
Hulten E, Jackson JL, Douglas K, George S, Villines TC..
The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials..
Arch Intern Med. , 166 (2006), pp. 1814-1821
[313]
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et-al..
Intensive versus moderate lipid lowering with statins after acute coronary syndromes..
N Engl J Med. , 350 (2004), pp. 1495-1504
[314]
Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et-al..
Expert consensus document on beta-adrenergic receptor blockers..
Eur Heart J. , 25 (2004), pp. 1341-1362
[315]
Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et-al..
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction..
Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. , 327 (1992), pp. 669-677
[316]
Torp-Pedersen C, Kober L..
Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction..
TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. , 354 (1999), pp. 9-12
[317]
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et-al..
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both..
N Engl J Med. , 349 (2003), pp. 1893-1906
[318]
Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA, Granger CB, et-al..
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006..
JAMA. , 297 (2007), pp. 1892-1900
[319]
Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et-al..
Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology..
Eur Heart J. , 27 (2006), pp. 1341-1381
[320]
Rahimi K, Watzlawek S, Thiele H, Secknus MA, Hayerizadeh BF, Niebauer J, et-al..
Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment..
Eur Heart J. , 27 (2006), pp. 1706-1711
Idiomas
Revista Española de Cardiología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.